Tag: development program

Ad hoc announcement pursuant to Art. 53 LR

- CMT-SORD program advances; meeting scheduled with the FDA in Q3 2025 to discuss govorestat for the treatment of CMT-SORD

TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2025 and provided an update on its business.

CALGARY, Alberta, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Petrus Resources Ltd. (“Petrus” or the “Company”) (TSX: PRQ) is pleased to report financial and operating results as at and for the three and six months ended June 30, 2025.

CALGARY, Alberta, Aug. 06, 2025 (GLOBE NEWSWIRE) -- NuVista Energy Ltd. ("NuVista" or the "Company") (TSX: NVA) is pleased to announce financial and operating results for the three and six months ended June 30, 2025, and to provide an update on our operational performance. We have continued to advance our business with the goal of creating top-tier returns for our shareholders. Our predictable and repeatable development plan continues to produce improved capital efficiencies, allowing us to reduce our capital expenditures guidance both this year and next and deliver average annual per share production growth of at least 15%. In the third quarter, we will be ramping up production toward 100,000 Boe/d and our 5-year outlook of growing production to 125,000 Boe/d remains fully in-tact and will be achieved with less capital than originally expected. With respect to returns to shareholders, we have directed over $100 million toward share repurchases in the first half of the year and continue to believe a balanced approach to absolute growth and share repurchases will drive superior total returns.

www.freyapharmasolutions.com

Conference call and webcast scheduled for August 4, 2025, at 8:00 a.m. EDT (2:00 p.m. CEST)

WARREN, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), today announced that it expects to receive $1 million in grant funding to advance Tevogen.AI, its artificial intelligence–powered drug discovery and development program.